Thursday, 15 October 2026European Markets

MANITOU BF And EXOR NV Have A High Dividend Yield And Return On Equity In The Farm & Heavy Construction Machinery Industry.

Loading stream...

(vianews) - manitou bf (mtu.pa) is among this list of stock assets with the highest dividend rate and return on equity on the farm & heavy construction machinery industry.

financial asset price forward dividend yield return on equity
manitou bf (mtu.pa) €25.35 7.48% 18.56%
exor nv (exo.as) €96.70 0.48% 51.37%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. manitou bf (mtu.pa)

7.48% forward dividend yield and 18.56% return on equity

manitou bf sa, together with its subsidiaries, engages in the development, manufacture, and provision of equipment and services worldwide. it operates in two divisions, product, and services and solutions. the company offers material handling, access, and earthmoving equipment, including rough-terrain fixed, rotating, and heavy-duty telehandlers; rough-terrain, semi-industrial, and industrial forklift trucks; skid-steer, articulated, backhoe, and track loaders; aerial work platforms; and truck-mounted forklifts, as well as warehousing equipment. it also provides attachments, such as buckets, clamps, cups, fork handling solutions, forks and grapples, jibs, work platforms, skips, sweepers and cleaners, winches, mining accessories, and miscellaneous attachments, as well as backrest, carriage, and interface references. in addition, the company offers value added services comprising technical training, new or refurbished spare parts, after-sales service, machine connectivity, fleet management, financing solutions, maintenance and warranty extension contracts, rent-to-rent leases, full-service contracts, recovery, repair, and resale of used equipment. the company offers its products through a network of dealers under the manitou, gehl, and mustang by manitou brands in agriculture, construction, industry, aeronautics, defense, environment, mining and quarries, and oil and gas markets. manitou bf sa was incorporated in 1954 and is headquartered in ancenis, france.

earnings per share

as for profitability, manitou bf has a trailing twelve months eps of €3.75.

pe ratio

manitou bf has a trailing twelve months price to earnings ratio of 6.76. meaning, the purchaser of the share is investing €6.76 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 18.56%.

moving average

manitou bf's value is way higher than its 50-day moving average of €18.59 and way above its 200-day moving average of €22.50.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, manitou bf's stock is considered to be overbought (>=80).

more news about manitou bf.

2. exor nv (exo.as)

0.48% forward dividend yield and 51.37% return on equity

exor n.v. engages in the luxury goods, automotive, agricultural and construction equipment, commercial vehicles, and professional football businesses worldwide. the company designs, engineers, produces, and sells luxury performance sports cars under the ferrari brand. it offers automotive vehicles and mobility solutions under the abarth, alfa romeo, chrysler, citroen, dodge, ds, fiat, fiat professional, jeep, lancia, maserati, mopar, opel, peugeot, ram, and vauxhall brands; and retail and dealer financing, and rental services for the automotive sector, as well as sells service parts. in addition, the company designs, produces, markets, sells, and finances agricultural and construction equipment, trucks, commercial vehicles, buses, engines, and car spare parts. further, it manages professional football teams under the juventus football club name; publishes the economist, il secolo xix, la repubblica and la stampa, and other newspapers and magazines; offers digital and advertising, and conference and electronic services; and operates three national radio stations, including radio deejay. additionally, the company provides furniture, homeware, apparel, leather goods, jewelry, and accessories; and offers footwear. the company was founded in 1899 and is headquartered in amsterdam, the netherlands. exor n.v. operates as a subsidiary of giovanni agnelli b.v.

earnings per share

as for profitability, exor nv has a trailing twelve months eps of €76.

pe ratio

exor nv has a trailing twelve months price to earnings ratio of 1.27. meaning, the purchaser of the share is investing €1.27 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 51.37%.

volume

today's last reported volume for exor nv is 31712 which is 76.9% below its average volume of 137334.

volatility

exor nv's last week, last month's, and last quarter's current intraday variation average was a positive 0.05%, a negative 0.04%, and a positive 0.96%.

exor nv's highest amplitude of average volatility was 0.36% (last week), 0.90% (last month), and 0.96% (last quarter).

moving average

exor nv's worth is higher than its 50-day moving average of €96.44 and below its 200-day moving average of €97.70.

more news about exor nv.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com